Safety and Pharmacokinetic Study of LYC-30937 in Subjects With Active Ulcerative Colitis

Inclusion Criteria: * Active ulcerative colitis defined as a Mayo endoscopy score of ≥ 2 despite therapy. * Male or female age 18 to 75 * May be receiving a therapeutic dose of an oral 5-amino salicylic acid compound or oral corticosteroid therapy Exclusion Criteria: * Current anti-tumor necrosis factor use * Current immunosuppressant use (Note: this does not include corticosteroid use) * Subjects with only distal active disease (i.e. proctitis) * Clinically significant active infection * Known bleeding disorder, a risk of bleeding or hypercoagulable disorders in which an anticoagulant is required * History of malignancy within the last 5 years except non-melanoma skin cancer or cervical carcinoma in situ * Clinically significant lab abnormalities (i.e. liver function abnormalities, renal insufficiency, abnormal absolute neutrophil count or hemoglobin) * History of colon resection * Any other investigational therapy or investigational biologics use within 8 weeks of investigational medicinal product administration